Physician profile
Heather Boyle
NPI 1245740315
$3,103.20
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $782 · 2022: $544 · 2023: $461 · 2024: $660 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.56 | 2023-2025 | Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $396.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $212.47 | 2022 | |
| Amgen INC. | $196.59 | 2021-2024 | Prolia, Evenity, Repatha |
| Exact Sciences Corporation | $132.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $114.52 | 2023-2025 | |
| Novo Nordisk INC | $72.86 | 2023-2024 | Wegovy |
| Glaxosmithkline, LLC. | $66.25 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Redhill Biopharma INC. | $65.99 | 2021 | |
| Boston Scientific Corporation | $61.36 | 2021-2023 | |
| Lilly USA, LLC | $51.99 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Stimwave Technologies Incorporated | $47.72 | 2021 | |
| Esperion Therapeutics, INC. | $41.75 | 2024 | Nexletol |
| Pfizer INC. | $38.97 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $33.43 | 2023 | Hetlioz |
| Supernus Pharmaceuticals, INC. | $29.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.40 | 2025 | Jardiance |
| Inspire Medical Systems, INC. | $23.17 | 2025 | Inspire |
| Indivior INC. | $19.50 | 2023 | Perseris |
| Biodelivery Sciences International, INC. | $19.36 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.08 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.63 | 2025 | Caplyta |
| Mylan Specialty L.P. | $15.34 | 2023 | Yupelri |
| Lundbeck LLC | $12.73 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.